398 related articles for article (PubMed ID: 17169007)
1. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
2. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
[TBL] [Abstract][Full Text] [Related]
3. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
Do Ngoc Thanh C; Audry G; Forin V
J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
[TBL] [Abstract][Full Text] [Related]
5. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.
Stoehrer M; Wolff A; Kramer G; Steiner R; Lmöchner-Ernst D; Leuth D; Steude U; Ruebben H
Urol Int; 2009; 83(4):379-85. PubMed ID: 19996642
[TBL] [Abstract][Full Text] [Related]
7. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
8. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
da Silva CM; Cruz F
Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
[TBL] [Abstract][Full Text] [Related]
9. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.
Cruz F; Dinis P
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):920-7. PubMed ID: 17705161
[TBL] [Abstract][Full Text] [Related]
10. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Harris MA; Harding C; Fulford S; Whiteway J
BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
[No Abstract] [Full Text] [Related]
11. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions.
Kuo HC
J Urol; 2003 Sep; 170(3):835-9. PubMed ID: 12913711
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
[TBL] [Abstract][Full Text] [Related]
14. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Fowler CJ
Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
[No Abstract] [Full Text] [Related]
16. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Schurch B
Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
[No Abstract] [Full Text] [Related]
17. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Haferkamp A
Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
[No Abstract] [Full Text] [Related]
18. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
20. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
